Hypercalcemia Explained: Causes, Symptoms, PTH-Based Diagnosis and Treatment

Hypercalcemia becomes much easier to diagnose when the article is built around one question: is the hypercalcemia genuine, and is PTH appropriately suppressed?

Hypercalcemia is an abnormally elevated concentration of calcium in the circulation; elevation of ionized calcium is particularly important because ionized calcium is the biologically active fraction.

Calcium circulates as ionized calcium, protein-bound calcium and calcium complexed with circulating anions. Interpretation should not begin and end with a total serum calcium number. Once genuine hypercalcemia is established, the most useful next question is whether PTH is appropriately suppressed.

Confirming Genuine Hypercalcemia

Total serum calcium includes ionized calcium, protein-bound calcium and complexed calcium. A significant proportion of protein-bound calcium is associated with albumin, so changes in protein concentration can influence total calcium without producing an equivalent change in ionized calcium.

An unexpected elevated total calcium should be interpreted with albumin, clinical context and ionized calcium when necessary. Dehydration and hemoconcentration can increase measured albumin and protein-bound calcium, so an isolated elevated total calcium result in a dehydrated patient may require reassessment after context is considered.

When total calcium interpretation is uncertain or accurate assessment of biologically active calcium is important, direct ionized calcium measurement can be useful. This is particularly relevant with albumin abnormalities, critical illness, acid-base disturbance or complex metabolic problems. For the physiology of calcium fractions and CaSR-PTH feedback, review Calcium Homeostasis Explained.

Symptoms of Hypercalcemia

Hypercalcemia can affect the kidneys, gastrointestinal tract, nervous system, skeletal muscle, cardiovascular system and bone. Symptoms become more likely as hypercalcemia becomes more severe or more acute.

• Neurological: fatigue, lethargy, reduced concentration, weakness and confusion; severe cases may cause marked altered mental status, stupor or coma.
• Gastrointestinal: anorexia, nausea, vomiting, constipation and abdominal discomfort.
• Muscular: muscle weakness, contrasting with the increased neuromuscular excitability of hypocalcemia.
• Renal: polyuria, polydipsia, dehydration, nephrolithiasis, nephrocalcinosis in selected chronic cases and deterioration in renal function.

The clinical effect depends not only on the absolute calcium concentration but also on speed of rise, duration, hydration, renal function, underlying cause and other metabolic abnormalities.

Why Hypercalcemia Causes Polyuria

Hypercalcemia can impair the kidney's concentrating ability and reduce responsiveness to vasopressin, producing a nephrogenic-DI-like concentrating defect that causes polyuria and water loss.

High calcium can interfere with renal responsiveness to vasopressin and with the medullary concentrating mechanism. This can resemble nephrogenic diabetes insipidus physiology, without implying that every patient with hypercalcemia has diabetes insipidus. The DI framework is explained in how nephrogenic diabetes insipidus impairs urine concentration.

This cycle is clinically important because volume depletion can amplify the calcium abnormality. Polyuria can also contribute to water deficit, a physiology discussed in Hypernatremia Explained.

Kidney and Bone Effects

Persistent hypercalcemia and/or hypercalciuria can increase the risk of renal stone formation, particularly in chronic disorders such as primary hyperparathyroidism.

Skeletal manifestations depend strongly on the cause. Conditions with excessive bone resorption can produce bone pain, reduced bone mineral density and fractures in more advanced disease. Not every patient with hypercalcemia has bone disease.

ECG Changes in Hypercalcemia

The classic ECG change in hypercalcemia is shortening of the QT interval, mainly due to shortening of the ST segment.

Increased extracellular calcium alters the ventricular action potential and shortens its plateau phase. Therefore hypercalcemia shortens ST duration and shortens the QT interval.

Severe calcium disturbances can affect cardiac conduction and rhythm, including bradyarrhythmias, conduction abnormalities and other rhythm disturbances, but not every patient with hypercalcemia develops an arrhythmia. This is the opposite classic ECG direction from hypocalcemia, which prolongs QT.

How PTH Guides Diagnosis

PTH should normally be suppressed when calcium is high. Elevated or inappropriately normal PTH suggests PTH-dependent hypercalcemia, while suppressed PTH suggests a non-PTH cause.

This is the central diagnostic concept. Normally, high calcium increases CaSR activation and suppresses PTH secretion. If PTH is within the reference range during confirmed hypercalcemia, it may still be inappropriately normal or inappropriately unsuppressed.

PTH-Dependent Hypercalcemia

PTH-dependent hypercalcemia means calcium is high but PTH is elevated or inappropriately normal. Think particularly about primary hyperparathyroidism, tertiary hyperparathyroidism, familial hypocalciuric hypercalcemia and lithium-associated physiology where appropriate.

Then assess phosphate, renal function, urinary calcium, medication history, CKD history and family or lifelong calcium history where relevant.

Primary Hyperparathyroidism

Primary hyperparathyroidism is a major cause of hypercalcemia. The fundamental abnormality is autonomous or inappropriate PTH secretion despite elevated calcium.

The typical pattern is calcium high, PTH high or inappropriately normal and phosphate often low because PTH increases renal phosphate excretion. Even if PTH is not numerically above the laboratory reference interval, failure to suppress PTH is abnormal in hypercalcemia.

Excessive PTH can contribute to hypercalcemia through increased renal calcium conservation, increased calcitriol production, increased intestinal calcium availability indirectly and increased skeletal calcium mobilization through altered bone remodelling.

Tertiary Hyperparathyroidism

Long-standing secondary hyperparathyroidism, particularly in advanced chronic kidney disease, can eventually become autonomous. The parathyroid glands continue producing excessive PTH even when the original stimulus no longer adequately explains the secretion.

The patient may have markedly elevated PTH with hypercalcemia. Renal disease and previous long-standing secondary hyperparathyroidism provide important clinical context.

Familial Hypocalciuric Hypercalcemia

Familial hypocalciuric hypercalcemia, or FHH, is an important differential diagnosis when hypercalcemia occurs with PTH not suppressed. It is usually caused by altered calcium sensing, most commonly involving the calcium-sensing receptor pathway.

Because calcium sensing is altered, the body effectively behaves as though a higher calcium concentration is acceptable. The typical phenotype is mild hypercalcemia, PTH normal or mildly elevated/inappropriately normal, and relatively low urinary calcium excretion.

Primary hyperparathyroidism and FHH can both show high calcium with PTH not suppressed, but their management differs substantially. Parathyroid surgery does not correct the underlying calcium-sensing abnormality of FHH.

Urinary calcium assessment and the calcium-creatinine clearance ratio can help distinguish FHH from primary hyperparathyroidism. Very low CCCR supports FHH, whereas higher urinary calcium clearance supports primary hyperparathyroidism, but there is overlap. Kidney function, vitamin D status, calcium intake and medications such as thiazides can influence urinary calcium.

PTH-Independent Hypercalcemia

If calcium is high and PTH is appropriately suppressed, the parathyroid glands are responding normally. The cause lies elsewhere.

Major categories include malignancy, vitamin D-related mechanisms, granulomatous disease, selected medications, immobilization in appropriate contexts and selected endocrine disorders. The next investigations should be selected according to clinical context, not ordered indiscriminately.

Malignancy-Associated Hypercalcemia

Malignancy is an important cause of clinically significant hypercalcemia, particularly when the calcium elevation is relatively acute, substantial or symptomatic. PTH should generally be suppressed.

The three important mechanisms are PTH-related peptide, osteolytic bone disease and increased calcitriol production in selected malignancies.

PTHrP

PTH-related peptide is produced by some tumors and can activate PTH receptors, causing hypercalcemia while the patient's endogenous PTH becomes suppressed.

PTHrP can produce PTH-like effects including increased renal calcium conservation, increased bone resorption and renal phosphate wasting. The pattern can include calcium high, PTH suppressed, PTHrP elevated and phosphate often reduced.

Osteolytic Hypercalcemia

Malignancy can also increase calcium through local or widespread bone destruction and resorption, releasing calcium from skeletal stores. This mechanism is particularly relevant in malignancies with substantial bone involvement.

Calcitriol-Producing Malignancy

Selected malignancies, particularly some lymphomas, can increase production of calcitriol. This increases intestinal calcium absorption and contributes to hypercalcemia. The expected PTH response is suppression.

The PTH result is usually the most useful first discriminator.

Vitamin D and Hypercalcemia

Excess vitamin D activity can increase intestinal calcium absorption and contribute to hypercalcemia. This may occur through excessive vitamin D intake or inappropriate calcitriol production. PTH should generally become suppressed.

Excessive vitamin D exposure can increase calcium absorption sufficiently to cause hypercalcemia. Evaluation should consider 25-hydroxyvitamin D when vitamin D excess is suspected. Do not use calcitriol as a routine test for every patient with hypercalcemia.

Granulomatous Disease

Activated macrophages in some granulomatous diseases can express 1-alpha-hydroxylase and convert 25(OH)D to calcitriol. This production is less tightly regulated by the normal renal endocrine feedback system.

This mechanism can occur in conditions such as sarcoidosis and selected infectious granulomatous diseases.

Medication-Related Hypercalcemia

Medication and supplement history should be reviewed in unexplained hypercalcemia. Relevant examples include thiazide diuretics, lithium, excessive calcium intake in appropriate contexts, excessive vitamin D exposure and vitamin A excess in selected situations.

Thiazide diuretics reduce urinary calcium excretion and can contribute to hypercalcemia or reveal previously unrecognized disorders such as primary hyperparathyroidism. Lithium can alter calcium-sensing/PTH physiology and may be associated with hyperparathyroid-type hypercalcemia.

Other Causes

Prolonged immobilization can increase bone resorption in selected patients, particularly when skeletal turnover is high. PTH should generally be suppressed.

Increased bone turnover in hyperthyroidism can occasionally produce hypercalcemia, but the calcium abnormality is usually not the dominant feature of the thyroid disorder. Adrenal insufficiency is a less common cause associated with hypercalcemia through multiple mechanisms and should be considered when supported by the wider clinical picture.

Diagnostic Approach to Hypercalcemia

Start with high total calcium. Ask whether the result is reproducible, what the albumin is, whether the patient is dehydrated and whether ionized calcium is needed. Do not start an extensive malignancy or endocrine work-up before establishing that the abnormality is real.

Immediately assess for significant dehydration, marked polyuria, vomiting, altered mental status, severe weakness, acute kidney injury, cardiac abnormalities or other features suggesting severe symptomatic hypercalcemia. Severe symptomatic disease requires treatment and investigation in parallel.

These are diagnostic patterns, not standalone diagnoses. Interpret them with clinical context, renal function, medications and appropriate confirmatory testing.

Treatment of Hypercalcemia

Management depends on calcium severity, symptoms, rate of rise, hydration, renal function and underlying mechanism. The major goals are to correct clinically important volume depletion, lower calcium when urgently necessary, reduce ongoing calcium release or absorption when appropriate, treat the underlying cause and monitor for treatment complications.

Mild, stable, asymptomatic hypercalcemia does not automatically require aggressive emergency calcium-lowering therapy. Management focuses on confirming the abnormality, establishing the cause, correcting reversible contributors, maintaining appropriate hydration and treating the underlying disease.

Significant symptomatic or severe hypercalcemia can require urgent treatment, particularly with neurological impairment, significant dehydration, renal dysfunction, major gastrointestinal symptoms or cardiac abnormalities.

Severe Symptomatic Hypercalcemia

IV Fluid

Many patients with significant hypercalcemia are volume depleted because of polyuria, reduced intake and sometimes vomiting. Volume depletion decreases renal calcium clearance and can worsen hypercalcemia. Restoring intravascular volume is an important initial treatment principle when volume depletion is present.

In appropriate patients, volume restoration is generally performed using isotonic saline. This restores extracellular volume, improves renal perfusion and increases renal calcium excretion. Fluid therapy must be individualized in patients with heart failure, significant kidney disease or other conditions limiting fluid tolerance.

Loop Diuretics

Routine loop diuretics should not be taught as standard calcium-lowering treatment. They may have a role when fluid overload requires management after appropriate volume restoration.

Calcitonin

Calcitonin can lower calcium relatively rapidly and can be useful while slower treatments begin working. Its major limitation is tachyphylaxis, so its calcium-lowering effect diminishes with repeated administration. Calcitonin is mainly short-term bridging therapy rather than definitive long-term treatment.

Antiresorptive Therapy

IV bisphosphonates inhibit osteoclast-mediated bone resorption and are particularly important in malignancy-associated hypercalcemia when increased bone resorption contributes significantly. Examples used clinically include zoledronic acid and pamidronate. They do not lower calcium as rapidly as calcitonin; their effect develops over days rather than hours, but lasts longer.

Denosumab inhibits RANKL-mediated osteoclast activity and can be useful in selected patients with hypercalcemia associated with malignancy, particularly when antiresorptive treatment is required, bisphosphonate therapy is inadequate or unsuitable, or renal impairment affects treatment choice.

Glucocorticoids and Dialysis

Glucocorticoids are not universal therapy for hypercalcemia. They are particularly useful in selected vitamin D or calcitriol-mediated hypercalcemia, such as granulomatous disease and selected lymphomas.

Dialysis may be considered in selected patients with severe refractory hypercalcemia, significant renal failure limiting calcium clearance, inability to tolerate fluid administration or insufficient response to other treatments. This is specialist-level emergency management.

Treat the Underlying Cause

Primary hyperparathyroidism may require parathyroid surgery when appropriate indications are met, but this article does not reproduce full surgical-indication guidance. Malignancy requires acute control of hypercalcemia when necessary and treatment of the underlying malignant process.

Vitamin D excess requires stopping inappropriate excess vitamin D exposure and managing the hypercalcemia according to severity, without instructing patients to discontinue medically prescribed therapy without clinical review. Granulomatous disease treatment targets the underlying inflammatory or infectious disorder and excessive calcitriol-mediated calcium absorption when present. Medication-related hypercalcemia requires review of contributing medications and supplements through appropriate clinical assessment.

Worked Clinical Cases

Case 1: Primary Hyperparathyroidism Pattern

A patient has repeatedly elevated calcium, upper-normal PTH and low phosphate. PTH is not truly normal, because during hypercalcemia PTH should be suppressed. This suggests PTH-dependent hypercalcemia, with primary hyperparathyroidism as an important possibility.

Case 2: Malignancy/PTHrP Pattern

A patient has relatively rapid symptomatic hypercalcemia, weight loss and known or suspected malignancy. Calcium is high, PTH is suppressed and PTHrP is elevated. This supports humoral hypercalcemia of malignancy.

Case 3: Calcitriol-Mediated Hypercalcemia

A patient has high calcium, suppressed PTH and elevated calcitriol with clinical evidence of granulomatous disease. Extrarenal calcitriol production can increase intestinal calcium absorption and cause hypercalcemia.

Case 4: FHH Pattern

A young adult has mild persistent hypercalcemia, no significant symptoms, similar calcium results documented previously, PTH not suppressed and relatively low urinary calcium. Consider familial hypocalciuric hypercalcemia.

Case 5: Severe Hypercalcemia With Dehydration

A patient presents with marked thirst, polyuria, vomiting, confusion and dehydration with significantly elevated calcium. Volume depletion is both a consequence and an amplifier of severe hypercalcemia.

Case 6: Tertiary Hyperparathyroidism

A patient with long-standing advanced CKD and prolonged secondary hyperparathyroidism develops high calcium with markedly elevated PTH. Consider tertiary hyperparathyroidism in the appropriate clinical context.

Case 7: Thiazide Exposure

A patient has mild hypercalcemia while taking a thiazide. The medication may contribute to reduced urinary calcium excretion or reveal previously unrecognized primary hyperparathyroidism.

Common Mistakes

• Misconception: High total calcium always means high ionized calcium. Reality: interpret albumin and clinical context.
• Misconception: Normal PTH excludes primary hyperparathyroidism. Reality: during hypercalcemia, PTH should be suppressed.
• Misconception: High calcium should cause high PTH. Reality: normal physiology is Ca2+ rises and PTH falls.
• Misconception: All hypercalcemia is caused by hyperparathyroidism. Reality: PTH-independent causes include malignancy, vitamin D mechanisms and other causes.
• Misconception: Malignancy hypercalcemia causes high endogenous PTH. Reality: endogenous PTH should usually be suppressed.
• Misconception: PTHrP and PTH are the same test. Reality: PTHrP is a distinct peptide.
• Misconception: Low urine calcium proves FHH. Reality: urinary calcium and CCCR are aids with overlap and confounders.
• Misconception: Every patient with hypercalcemia needs aggressive IV treatment. Reality: treatment intensity depends on severity, symptoms and mechanism.
• Misconception: Loop diuretics are routinely required. Reality: routine forced diuresis is not the standard approach.
• Misconception: Calcitonin is definitive long-term therapy. Reality: it works rapidly but is limited by tachyphylaxis.
• Misconception: Bisphosphonates work immediately. Reality: they usually take longer to produce the major calcium-lowering effect.
• Misconception: Hypercalcemia prolongs QT. Reality: the classic association is short QT.

Key Clinical Pearls

Once genuine hypercalcemia is confirmed, ask whether PTH is suppressed. That single question separates most cases into PTH-dependent versus PTH-independent hypercalcemia.

• Ionized calcium is the biologically active fraction.
• Hypercalcemia can impair renal concentrating ability.
• Dehydration can worsen hypercalcemia by reducing renal calcium clearance.
• The classic ECG association is QT shortening.
• A numerically normal PTH may be pathologically inappropriate in hypercalcemia.
• FHH can mimic primary hyperparathyroidism.
• PTHrP-mediated hypercalcemia suppresses endogenous PTH.
• Treatment must address the underlying mechanism.

Frequently Asked Questions

Key Take-Home Messages

Hypercalcemia becomes much easier to diagnose when approached physiologically. First ask whether the hypercalcemia is genuine by considering total calcium, albumin, hydration and ionized calcium when necessary.

Then ask whether PTH is suppressed. High calcium with PTH high or inappropriately normal means PTH-dependent hypercalcemia. Think about primary hyperparathyroidism, FHH and tertiary hyperparathyroidism. High calcium with suppressed PTH means PTH-independent hypercalcemia. Consider malignancy, vitamin D or calcitriol mechanisms, granulomatous disease, medications and other context-specific causes.

Treatment has two dimensions: control dangerous hypercalcemia and correct the mechanism causing it.